2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2004090735v1 16/4/892    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Scalera, F. Articles by Bode-Böger, S. M. Search for Related Content PubMed PubMed Citation Articles by Scalera, F. Articles by Bode-Böger, S. M.

Erythropoietin Increases Asymmetric Dimethylarginine in Endothelial Cells: Role of Dimethylarginine Dimethylaminohydrolase

Fortunato Scalera^*, Jan T. Kielstein, Jens Martens-Lobenhoffer^*, Sylvia C. Postel^*, Michael Täger and Stefanie M. Bode-Böger^*

^* Institute of Clinical Pharmacology, University Hospital Otto-von-Guericke University, Magdeburg; Department of Internal Medicine, Division of Nephrology, Medical School Hannover, Hannover; and Institute of Medical Technology, Magdeburg, Germany

Address correspondence to: Prof. Stefanie M. Bode-Böger, Institute of Clinical Pharmacology, University Hospital, Otto-von-Guericke University, Leipziger Strasse, 44 D-39120, Magdeburg, Germany. Phone: +49-3916713060; Fax: +49-3916713062; E-mail:stefanie.bode-boeger{at}medizin.uni-magdeburg.de

Received for publication September 6, 2004. Accepted for publication January 5, 2005.

Recombinant human erythropoietin therapy frequently causes hypertension in humans and animals with chronic renal failure. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthase, and its accumulation has been associated with reducing NO bioavailability and increasing superoxide generation. Whether epoetin (EPO) or darbepoetin (NESP) can modify the levels of ADMA in endothelial cells was investigated. Endothelial cells from the third passage were incubated for 24 h in the presence of various concentrations of EPO or NESP (0, 0.1, 1, 10, 50, 100, and 200 U/ml). The levels of ADMA, allantoin, nitrate, and nitrite in conditioned media and the activity of dimethylarginine dimethylaminohydrolase (DDAH), the content of thiols and reactive oxygen species in endothelial cells, were determined. When endothelial cells were exposed to EPO or NESP, ADMA concentration in the cell culture medium increased significantly in a dose-dependent manner versus control. This effect was associated with a reduced activity of DDAH, the enzyme that degrades ADMA. Furthermore, EPO- or NESP-induced accumulation of ADMA was accompanied by a significant reduction of NO synthesis and an increase in oxidative stress. Both allantoin, a marker of oxygen free radical generation, and reactive oxygen species increased significantly after EPO or NESP treatment compared with control. The antioxidant pyrrolidine dithiocarbamate preserved DDAH activity and reduced ADMA accumulation in the same way as the co-incubation with anti-EPO neutralizing antibody. EPO and NESP posttranslationally impair DDAH activity via increased oxidative stress, causing ADMA as an important cardiovascular risk factor to accumulate and inhibit NO synthesis.

This article has been cited by other articles:

				N. D. Vaziri and X. J. Zhou Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease Nephrol. Dial. Transplant., November 5, 2008; (2008) gfn601v1. [Full Text] [PDF]

				S. S. Billecke, L. G. D'Alecy, R. Platel, S. E. Whitesall, K. A. Jamerson, R. L. Perlman, and C. A. Gadegbeku Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease Nephrol. Dial. Transplant., September 15, 2008; (2008) gfn500v1. [Abstract] [Full Text] [PDF]

				A. Desai, Y. Zhao, and J. S. Warren Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1513 - 1520. [Abstract] [Full Text] [PDF]

				C. Baylis Nitric oxide deficiency in chronic kidney disease Am J Physiol Renal Physiol, January 1, 2008; 294(1): F1 - F9. [Abstract] [Full Text] [PDF]

				F. Palm, M. L. Onozato, Z. Luo, and C. S. Wilcox Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3227 - H3245. [Abstract] [Full Text] [PDF]

				S. Swaminathan and S. V. Shah New Insights into Nephrogenic Systemic Fibrosis J. Am. Soc. Nephrol., October 1, 2007; 18(10): 2636 - 2643. [Abstract] [Full Text] [PDF]

				K. E. Jie, M. C. Verhaar, M.-J. M. Cramer, K. van der Putten, C. A. J. M. Gaillard, P. A. Doevendans, H. A. Koomans, J. A. Joles, and B. Braam Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors Am J Physiol Renal Physiol, November 1, 2006; 291(5): F932 - F944. [Abstract] [Full Text] [PDF]

				S. M. Bode-Boger, F. Scalera, J. T. Kielstein, J. Martens-Lobenhoffer, G. Breithardt, M. Fobker, and H. Reinecke Symmetrical Dimethylarginine: A New Combined Parameter for Renal Function and Extent of Coronary Artery Disease J. Am. Soc. Nephrol., April 1, 2006; 17(4): 1128 - 1134. [Abstract] [Full Text] [PDF]

				H. Morimoto, K. Nakao, K. Fukuoka, A. Sarai, A. Yano, T. Kihara, S. Fukuda, J. Wada, and H. Makino Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2775 - 2782. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673